These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 36918269)

  • 41. Inhibiting the Secretion of Hepatitis B Surface Antigen (HBsAg) to Treat Hepatitis B Infection- a Review.
    Baugh SDP
    Infect Disord Drug Targets; 2017; 17(1):24-35. PubMed ID: 28056752
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The scientific basis of combination therapy for chronic hepatitis B functional cure.
    Lim SG; Baumert TF; Boni C; Gane E; Levrero M; Lok AS; Maini MK; Terrault NA; Zoulim F
    Nat Rev Gastroenterol Hepatol; 2023 Apr; 20(4):238-253. PubMed ID: 36631717
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Decreased neonatal hepatitis B virus (HBV) viremia by maternal tenofovir treatment predicts reduced chronic HBV infection in children born to highly viremic mothers.
    Chang KC; Chang MH; Lee CN; Chang CH; Wu JF; Ni YH; Wen WH; Shyu MK; Lai MW; Chen SM; Hu JJ; Lin HH; Hsu JJ; Mu SC; Lin YC; Liu CJ; Chen DS; Lin LH; Chen HL;
    Aliment Pharmacol Ther; 2019 Aug; 50(3):306-316. PubMed ID: 31271463
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Laboratory diagnosis of hepatitis B].
    Forns X; Sánchez-Tapias JM
    Gastroenterol Hepatol; 2001 Feb; 24 Suppl 1():7-14. PubMed ID: 11279897
    [No Abstract]   [Full Text] [Related]  

  • 45. [New serological markers as a monitoring indicator for clinical cure of chronic hepatitis B].
    Wang XM; Niu JQ
    Zhonghua Gan Zang Bing Za Zhi; 2018 Aug; 26(8):565-567. PubMed ID: 30317786
    [TBL] [Abstract][Full Text] [Related]  

  • 46. End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB.
    Huang D; Wu D; Wang P; Wang Y; Yuan W; Hu D; Hu J; Wang Y; Tao R; Xiao F; Zhang X; Wang X; Han M; Luo X; Yan W; Ning Q
    J Hepatol; 2022 Jul; 77(1):42-54. PubMed ID: 35149125
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Update on hepatitis B virus infection.
    You CR; Lee SW; Jang JW; Yoon SK
    World J Gastroenterol; 2014 Oct; 20(37):13293-305. PubMed ID: 25309066
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Response predictors to treatment with pegylated interferon in chronic hepatitis B.
    Ferreira PR; Tenore Sde B
    Braz J Infect Dis; 2010; 14(5):519-25. PubMed ID: 21221484
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immune checkpoint inhibitors in chronic hepatitis B: therapy or high-risk factor for reactivation?
    Cai C; Zhang HF; Yang NB; Lu MQ
    Hepatol Int; 2022 Apr; 16(2):480-481. PubMed ID: 35332508
    [No Abstract]   [Full Text] [Related]  

  • 50. [Evidence based antiviral therapy for chronic hepatitis B].
    Okanoue T; Minami M
    Nihon Shokakibyo Gakkai Zasshi; 2005 Oct; 102(10):1253-8. PubMed ID: 16262155
    [No Abstract]   [Full Text] [Related]  

  • 51. Hepatitis B Surface Antigen Levels Are Related to Spontaneous Hepatitis B Surface Antigen Seroconversion in Inactive Hepatitis B Carriers.
    Wu CF; Fong TM; Wu SS; Saab S
    J Clin Gastroenterol; 2020 Jul; 54(6):573-576. PubMed ID: 32049690
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hepatic histologic and immunohistochemical changes in chronic hepatitis B after prolonged clearance of hepatitis B e antigen and hepatitis B surface antigen.
    Perrillo RP; Brunt EM
    Ann Intern Med; 1991 Jul; 115(2):113-5. PubMed ID: 2058858
    [No Abstract]   [Full Text] [Related]  

  • 53. Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B.
    Jeng WJ; Chen YC; Chien RN; Sheen IS; Liaw YF
    Hepatology; 2018 Aug; 68(2):425-434. PubMed ID: 29108132
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical Analysis of Polyethylene Glycol Interferon-α Treatment in 155 Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) Patients.
    Luo X; Yu JX; Xie L; Ma WJ; Wang LH
    Ann Hepatol; 2017 November-December,; 16(6):888-892. PubMed ID: 29055925
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Clinical analysis of seroconversion of HBsAg in chronic hepatitis B patients treated with PegIFN alpha-2a].
    Yang F; Wu XF; Li XH; Wei N
    Zhonghua Gan Zang Bing Za Zhi; 2009 Dec; 17(12):950-1. PubMed ID: 20038343
    [No Abstract]   [Full Text] [Related]  

  • 56. [Natural course and recommendation of therapy for HBV infection].
    Yatsuhashi H; Nagaoka S; Abiru S
    Nihon Shokakibyo Gakkai Zasshi; 2007 Oct; 104(10):1450-8. PubMed ID: 17917392
    [No Abstract]   [Full Text] [Related]  

  • 57. Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment.
    Fung J; Lai CL; Young J; Wong DK; Yuen J; Seto WK; Yuen MF
    Am J Gastroenterol; 2011 Oct; 106(10):1766-73. PubMed ID: 21826112
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Quantification of serum hepatitis B surface antigen: is it useful for the management of chronic hepatitis B?
    Janssen HL; Sonneveld MJ; Brunetto MR
    Gut; 2012 May; 61(5):641-5. PubMed ID: 22180061
    [No Abstract]   [Full Text] [Related]  

  • 59. Challenges in therapy of chronic hepatitis B.
    Hoofnagle JH
    J Hepatol; 2003; 39 Suppl 1():S230-5. PubMed ID: 14708709
    [No Abstract]   [Full Text] [Related]  

  • 60. Chronic hepatitis B in children and adolescents.
    Paganelli M; Stephenne X; Sokal EM
    J Hepatol; 2012 Oct; 57(4):885-96. PubMed ID: 22634122
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.